Industry

Up-LIFT study achieves primary endpoint: Statistically significant and clinically meaningful improvement in upper extremity strength and functioni Improvement in arm and hand function is the highest priority among people with tetraplegiaii Up-LIFT is the first large-scale clinical study of non-invasive spinal cord stimulation technology ONWARD plans to submit for marketing approval in the U.S. and … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the pricing of an upsized underwritten public offering of 8,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $25.00 … [Read more…]

In less than two years, Gilead has more than doubled the cost of its HIV medication, Descovy, for the lifesaving 340B program from $445.11 in Q3, 2020 to $987.55 in Q2, 2022 AHF will host a protest Tuesday, Sept. 13th targeting Gilead Sciences—”Greediad”—and its investors over its AIDS drug pricing during the annual Morgan Stanley … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its B-cell lymphoma-2 (BCL2) inhibitor ICP-248, which is the Company’s fifth innovative drug to enter the clinical stage in the field of hematology, and also the 13th … [Read more…]

BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (HKEX:1228) , a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, today announced that it will be participating in two upcoming investor conferences. Morgan Stanley 20th Annual Global Healthcare Conference (New York) CEO, James … [Read more…]

Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumour response in Non-Small Cell Lung Cancer Combination of PDC*lung01 at low dose with pembrolizumab resulted in Objective Response Rate and Progression Free Survival at nine months of 66.7% LIÈGE, Belgium & GRENOBLE, France–(BUSINESS WIRE)–PDC*line … [Read more…]

BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release dated August 29, 2022, the Company and its auditors are continuing to work diligently to complete the audit of the Company’s annual financial statements for the fiscal … [Read more…]

Report available at corporateresponsibility.unither.com SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its third annual Corporate Responsibility Report with 2021 highlights, providing stakeholders important information regarding the company’s commitment to environmental, social, and governance (ESG) priorities. Contained within the report … [Read more…]

CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Matt Trerotola has joined its Board of Directors. Matt has served as the President and Chief Executive Officer for Enovis Corporation (formerly Colfax), an innovation-driven medical technology company, since … [Read more…]

Company to hold conference call and webcast on Monday, September 12th at 4:30 PM Eastern Standard Time (EST) VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented preliminary results from the company’s Phase 1 clinical trial evaluating zanidatamab zovodotin (ZW49) for the treatment of HER2-positive tumors. … [Read more…]